Literature DB >> 11469970

Chronic Visceral Right Upper Quadrant Pain Without Gallstones.

Sanjeeb Shrestha1, Pankaj J. Pasricha.   

Abstract

Patients with chronic visceral right upper quadrant pain without gallstones can be broadly categorized into two groups: patients with gallbladder dyskinesia, and patients with sphincter of Oddi dysfunction (SOD). Treating patients with these disorders is often challenging to clinicians due to the difficulty at arriving at a definite diagnosis, and the lack of efficacy of various treatment modalities. The only real treatment option for patients with gallbladder dyskinesia is cholecystectomy; however, the results are difficult to predict in an individual patient. Patients with SOD can be approached according to a classification that at least partially reflects the underlying pathophysiology. Patients with type I SOD have underlying papillary stenosis, and benefit from empiric sphincterotomy. Patients with type II SOD may have muscle spasm as predominant pathophysiology; this group of patients benefit from sphincterotomy only if increased sphincter pressure is demonstrated by sphincter of Oddi manometry. Patients with type III SOD may have visceral hyperalgesia; a trial of antidepressants or a therapeutic trial with botulinum toxin injection into the ampulla should be considered prior to more invasive endoscopic therapy.

Entities:  

Year:  2001        PMID: 11469970     DOI: 10.1007/s11938-001-0024-4

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  26 in total

1.  Endoscopic injection of botulinum toxin for biliary sphincter of Oddi dysfunction.

Authors:  T Wehrmann; H Seifert; M Seipp; B Lembcke; W F Caspary
Journal:  Endoscopy       Date:  1998-10       Impact factor: 10.093

2.  Sphincter of Oddi dysfunction and acute pancreatitis.

Authors:  J W Chen; G T Saccone; J Toouli
Journal:  Gut       Date:  1998-09       Impact factor: 23.059

Review 3.  Defining sphincter of oddi dysfunction.

Authors:  P Funch-Jensen
Journal:  Gastrointest Endosc Clin N Am       Date:  1996-01

4.  Efficacy of nifedipine therapy in patients with sphincter of Oddi dysfunction: a prospective, double-blind, randomized, placebo-controlled, cross over trial.

Authors:  M S Khuroo; S A Zargar; G N Yattoo
Journal:  Br J Clin Pharmacol       Date:  1992-05       Impact factor: 4.335

5.  Does endoscopic sphincterotomy destroy the function of Oddi's sphincter?

Authors:  P M Heinerman; A H Graf; O Boeckl
Journal:  Arch Surg       Date:  1994-08

6.  Complications of endoscopic sphincterotomy. A prospective series with emphasis on the increased risk associated with sphincter of Oddi dysfunction and nondilated bile ducts.

Authors:  S Sherman; T A Ruffolo; R H Hawes; G A Lehman
Journal:  Gastroenterology       Date:  1991-10       Impact factor: 22.682

7.  Endoscopic sphincterotomy for suspected dysfunction of the sphincter of Oddi.

Authors:  B S Thatcher; M V Sivak; F J Tedesco; J A Vennes; S W Hutton; E A Achkar
Journal:  Gastrointest Endosc       Date:  1987-04       Impact factor: 9.427

8.  Acalculous biliary pain: cholecystectomy alleviates symptoms in patients with abnormal cholescintigraphy.

Authors:  L Yap; A G Wycherley; A D Morphett; J Toouli
Journal:  Gastroenterology       Date:  1991-09       Impact factor: 22.682

9.  Transduodenal sphincteroplasty with transampullary septectomy for stenosing papillitis.

Authors:  F G Moody; R Vecchio; R Calabuig; N Runkel
Journal:  Am J Surg       Date:  1991-02       Impact factor: 2.565

10.  Is endoscopic sphincterotomy for disabling biliary-type pain after cholecystectomy effective?

Authors:  I C Roberts-Thomson; J Toouli
Journal:  Gastrointest Endosc       Date:  1985-12       Impact factor: 9.427

View more
  2 in total

1.  Gastrointestinal Uses of Botulinum Toxin.

Authors:  Maria Cariati; Maria Michela Chiarello; Marco Cannistra'; Maria Antonietta Lerose; Giuseppe Brisinda
Journal:  Handb Exp Pharmacol       Date:  2021

Review 2.  Treatment of gastrointestinal sphincters spasms with botulinum toxin A.

Authors:  Giuseppe Brisinda; Nicola Sivestrini; Giuseppe Bianco; Giorgio Maria
Journal:  Toxins (Basel)       Date:  2015-05-29       Impact factor: 4.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.